Literature DB >> 2085111

Nitrofurantoin versus trimethoprim prophylaxis in recurrent urinary tract infection in children. A randomized, double-blind study.

L Brendstrup1, K Hjelt, K E Petersen, S Petersen, E A Andersen, P S Daugbjerg, B R Stagegaard, O H Nielsen, R Vejlsgaard, G Schou.   

Abstract

The efficiency of nitrofurantoin and trimethoprim prophylaxis in preventing recurrent urinary tract infections (UTI) was compared by means of actuarial percentage recurrence-free curves in a randomized, double blind study in 130 children (126 girls, 4 boys) aged 1 to 14 years (mean 7.5). The children received the antibiotics for 6 months. Nitrofurantoin proved to be the most efficient prophylactic drug in patients with abnormal urography and/or reflux (n = 60) as evaluated by actuarial percentage recurrence-free analysis (p = 0.0025). However, no differences was found in patients without urinary tract abnormalities. Nitrofurantoin prophylaxis altered neither the pattern of resistance nor the bacteriological constellation, while patients receiving trimethoprim prophylaxis had 76% trimethoprim resistant bacteria during prophylaxis, compared with 8% before (p less than 0.0001) and 17% after (p less than 0.0001) prophylaxis. The percentage of recurrences due to E. coli (70-80%) was unaffected by trimethoprim prophylaxis, but the proportion due to trimethoprim resistant E. coli was significantly higher during prophylaxis (65%) than before (6%, p less than 0.0001) and after (11%, p less than 0.001). The percentage of Staphylococcus epidermidis UTI was significantly higher during trimethoprim prophylaxis (27%) than before (2%, p less than 0.0003). Following prophylaxis there was no difference in the actuarial percentage recurrence-free curves of the two regimens. Side effects occurred more frequently in the nitrofurantoin group (37%) than in the trimethoprim group (21%) (p = 0.05). The majority of side effects in the nitrofurantoin group derived from gastrointestinal symptoms. In conclusion, nitrofurantoin is recommended as the first choice prophylactic treatment of children with recurrent UTI and urinary tract abnormalities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2085111     DOI: 10.1111/j.1651-2227.1990.tb11414.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  7 in total

Review 1.  May we go on with antibacterial prophylaxis for urinary tract infections?

Authors:  R Beetz
Journal:  Pediatr Nephrol       Date:  2005-10-21       Impact factor: 3.714

Review 2.  Children's UTIs in the new millennium. Diagnosis, investigation, and treatment of childhood urinary tract infections in the year 2001.

Authors:  C T White; D G Matsell
Journal:  Can Fam Physician       Date:  2001-08       Impact factor: 3.275

Review 3.  Controversies in the diagnosis and management of urinary tract infections in children.

Authors:  Gaurang Shah; Jyoti Upadhyay
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 4.  Evaluating the benefits of antimicrobial prophylaxis to prevent urinary tract infections in children: a systematic review.

Authors:  N Le Saux; B Pham; D Moher
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

5.  Long-term antibiotics for preventing recurrent urinary tract infection in children.

Authors:  Gabrielle Williams; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2019-04-01

Review 6.  The Bucherer-Bergs Multicomponent Synthesis of Hydantoins-Excellence in Simplicity.

Authors:  Martin Kalník; Peter Gabko; Maroš Bella; Miroslav Koóš
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

7.  Medical management of vesicoureteral reflux--quiz within the article. Don't overlook placebos.

Authors:  Tej K Mattoo
Journal:  Pediatr Nephrol       Date:  2007-05-05       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.